SCHEMBL24229999

SCHEMBL24229999

COC(=O)c1ccc(C#Cc2ccc(F)cc2F)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.51
RAB9A P51151 5/20 0.51
MAPT P10636 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
LMNA P02545 1/20 0.51
PTPN11 Q06124 1/20 0.49
KMT2A Q03164 5/20 0.47
MEN1 O00255 3/20 0.47
MAPK1 P28482 2/20 0.47
HTT P42858 1/20 0.47
ATM Q13315 1/20 0.46
KDM4E B2RXH2 1/20 0.43
MAP2K4 P45985 1/20 0.43
ALDH1A1 P00352 1/20 0.43
GRM5 P41594 1/20 0.41
POLB P06746 1/20 0.41
CTDSP1 Q9GZU7 1/20 0.41
PTGDR2 Q9Y5Y4 1/20 0.41
PARP1 P09874 1/20 0.41
ACACB O00763 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24230270 0.85 KMT2A (0.62) NPC1RAB9AMAPTPTPN11KMT2A
SCHEMBL25559102 0.83 ACACB (0.44) NPC1RAB9ASMN1; SMN2HTTGRM5
SCHEMBL15014372 0.83 EGFR (0.53) RAB9AMAPTPTPN11KMT2AKDM4E
SCHEMBL24230149 0.82 ALDH1A1 (0.55) NPC1RAB9AMAPTSMN1; SMN2LMNA
SCHEMBL29374341 0.82 ALDH1A1 (0.55) NPC1RAB9AMAPTSMN1; SMN2LMNA
SCHEMBL24230222 0.82 FFAR1 (0.47) NPC1RAB9ASMN1; SMN2PTPN11GRM5
SCHEMBL24230087 0.81 CYP1A2 (0.45) PTPN11KMT2AHTTKDM4EALDH1A1
SCHEMBL14059555 0.79 KMT2A (0.56) NPC1RAB9AMAPTSMN1; SMN2LMNA
SCHEMBL69268 0.79 PTPN11 (0.69) RAB9AMAPTPTPN11KMT2AMEN1
SCHEMBL16420900 0.79 POLB (0.50) NPC1RAB9AMAPTPTPN11KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250332138-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDER VIVOZON, INC. (KR) 2025-10-30 US disclosed
US-12435051-B2 Dual modulator of mGluR5 and 5-HT2A receptor, and use thereof VIVOZON, INC. (KR) 2025-10-07 US disclosed
EP-4470534-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDER Vivozon, Inc. (KR) 2024-12-04 EP disclosed
US-20240360092-A1 DUAL MODULATOR OF MGLUR5 AND 5-HT2A RECEPTOR, AND USE THEREOF VIVOZON INC. (KR) 2024-10-31 US disclosed
US-12060339-B2 Dual modulator of mGluR5 and 5-HT2A receptor, and use thereof VIVOZON INC. (KR) 2024-08-13 US disclosed
EP-4190770-A1 DUAL REGULATOR FOR MGLUR5 AND 5-HT2A RECEPTORS AND USE THEREOF Vivozon, Inc. (KR) 2023-06-07 EP disclosed
EP-4190770-A1 DUAL REGULATOR FOR MGLUR5 AND 5-HT2A RECEPTORS AND USE THEREOF Vivozon, Inc. (KR) 2023-06-07 EP disclosed
CN-116234552-A Dual modulators of mGluR5 and 5-HT2A receptors and uses thereof (株)倍宝尊 2023-06-06 CN disclosed
US-20220274939-A1 DUAL MODULATOR OF MGLUR5 AND 5-HT2A RECEPTOR, AND USE THEREOF VIVOZON INC. (KR) 2022-09-01 US disclosed
WO-2022025636-A1 DUAL REGULATOR FOR MGLUR5 AND 5-HT2A RECEPTORS AND USE THEREOF 주식회사 비보존 2022-02-03 WO disclosed
WO-2022025636-A1 DUAL REGULATOR FOR MGLUR5 AND 5-HT2A RECEPTORS AND USE THEREOF 주식회사 비보존 2022-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12435051-B2 Dual modulator of mGluR5 and 5-HT2A receptor, and use thereof GRM5, HTR5A, HTR2A NPC1 4272/4885RAB9A 1193/4885MAPT 3933/4885
US-20240360092-A1 DUAL MODULATOR OF MGLUR5 AND 5-HT2A RECEPTOR, AND USE THEREOF GRM5, HTR5A, HTR2A NPC1 4272/4885RAB9A 1193/4885MAPT 3933/4885
US-12060339-B2 Dual modulator of mGluR5 and 5-HT2A receptor, and use thereof GRM5, HTR5A, HTR2A NPC1 4272/4885RAB9A 1193/4885MAPT 3933/4885
US-20250332138-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDER GRM5, HTR5A, HTR2A NPC1 1085/4885RAB9A 1072/4885MAPT 864/4885
US-20220274939-A1 DUAL MODULATOR OF MGLUR5 AND 5-HT2A RECEPTOR, AND USE THEREOF GRM5, HTR5A, HTR2A NPC1 4272/4885RAB9A 1193/4885MAPT 3933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.